Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)‘s stock had its “buy” rating restated by stock analysts at Canaccord Genuity in a research note issued to investors on Saturday. They presently have a $10.00 price objective on the stock. Canaccord Genuity’s price target would suggest a potential upside of 112.77% from the company’s current price.
A number of other analysts have also weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Wednesday. FBR & Co reiterated an “outperform” rating and set a $9.00 target price on shares of Aurinia Pharmaceuticals in a research note on Tuesday. Finally, Leerink Swann reiterated an “outperform” rating and set a $7.00 target price on shares of Aurinia Pharmaceuticals in a research note on Monday, October 3rd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $7.75.
Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 4.70 on Friday. The firm’s 50 day moving average price is $2.45 and its 200-day moving average price is $2.78. The stock’s market cap is $165.84 million. Aurinia Pharmaceuticals has a 1-year low of $1.42 and a 1-year high of $5.69.
An institutional investor recently raised its position in Aurinia Pharmaceuticals stock. Lombard Odier Asset Management USA Corp raised its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 2.8% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 102,294 shares of the company’s stock after buying an additional 2,813 shares during the period. Lombard Odier Asset Management USA Corp owned 0.29% of Aurinia Pharmaceuticals worth $283,000 at the end of the most recent reporting period. 20.04% of the stock is owned by hedge funds and other institutional investors.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.